CTOs on the Move


 
Tanox, Inc. is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.tanox.com
  • 4888 Loop Central Dr Ste 820
    Houston, TX USA 77081
  • Phone: 713.578.4000

Executives

Name Title Contact Details

Similar Companies

Theranos

Our mission is to make actionable information accessible to everyone at the time it matters. By making actionable information accessible to everyone in the world at the time it matters most, we are working to facilitate the early detection and prevention of disease, and empower people everywhere to live their best possible lives.

moksha8 Pharmaceuticals

moksha8 Pharmaceuticals is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FASgen

FASgen is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Willow Industries

Willow Industries Ozone Systems. Mitigate Mold & Bacteria. Willow systems provide clean and effective solutions to cannabis contamination.

ImmunoGen

Targeting a better life for people with cancer is why we get up in the morning. It`s not enough to disrupt the progress of someone`s cancer; we want to keep cancer from disrupting someone`s life. That`s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class folate receptor alpha (FRα)-targeting ADC with multiple studies underway in ovarian cancer. Our second pivotal program, IMGN632, is a CD123-targeting ADC being studied as a monotherapy in BPDCN and in combination in AML. Our earlier-stage assets in development are IMGC936, an ADAM9-targeting ADC in co-development with MacroGenics, and IMGN151, our next generation anti-folate receptor alpha ADC.